Stimart Tryn 4
4 · AbCellera Biologics Inc. · Filed Dec 17, 2020
Insider Transaction Report
Form 4
Stimart Tryn
Chief Legal Officer
Transactions
- Award
Stock Option (right to buy)
2020-12-10+190,800→ 190,800 totalExercise: $20.00Exp: 2030-12-10→ Common Shares (190,800 underlying) - Purchase
Common Shares
2020-12-15$20.00/sh+250$5,000→ 250 total - Purchase
Common Shares
2020-12-15$20.00/sh+250$5,000→ 250 total(indirect: By Spouse) - Award
Stock Option (right to buy)
2020-10-29+850,000→ 850,000 totalExercise: $2.41Exp: 2030-10-29→ Common Shares (850,000 underlying)
Footnotes (5)
- [F1]On December 4, 2020, the Issuer effected a one-for-10 forward stock split of the Issuer's Common Shares ("Stock Split"). This amount has been adjusted to give effect to the Stock Split.
- [F2]The exercise price reported above was converted from the Canadian exercise price of CAD $3.08 using an exchange rate of CAD $1.27840 = US $1.00.
- [F3]25% of the shares subject to such option vest and become exercisable on October 29, 2021 and the remainder of the shares vest in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
- [F4]25% of the shares subject to such option vest and become exercisable on December 31, 2021 and the remainder of the shares vest in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
- [F5]This transaction occurred prior to the effectiveness of the Issuer's registration under Section 12 of the Securities Exchange Act of 1934 and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3.